

22852
PATENT TRADEMARK OFFICE

Sir:

PATENT Attorney Docket No. 08888.0549

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	#6
Shian-Jiun SHIH et al.) Group Art Unit: 1632
Application No.: 09/763,210) Examiner: Not yet assigned
Filed: October 16, 2001)) DEGE
For: ADENOVIRUS FORMULATIONS FOR GENE THERAPY	RECEIVED NOV 1 5 2002
Commissioner for Patents Washington, DC 20231	TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. To the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits for this application.

Copies of the listed documents, including any copending patent applications, are attached. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

For the following foreign language documents, Applicants submit the indicated English language equivalents:

EP 0 185573B1

U.S. Patent No. 6,426,216;

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com EP 0 198745B1 U.S. Patent No. 5,037,744;

EP 0 200590B1 U.S. Patent No. 4,914,027;

EP 0 236210B1 U.S. Patent No. 5,100,784;

EP 0 319067B1 U.S. Patent No. 4,990,447;

WO 96/22378 U.S. Patent No. 6,127,175; and

WO 97/33975 U.S. Patent No. 6,248,588.

As described in the specification at page 11, WO95/02697 discloses examples of E1/E4 deleted adenoviruses.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: November 14, 2002

Steven P. O'Connor

Reg. No. 41,225

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

Atty. Docket No.	08888.0549	Appln. No.	09/763,210	RECEIVED
Applicant	Shian-Jiun SHIH et al.	•		NOV 1 5 2002
Filing Date	October 16, 2001	Group:	1632	
				TECH CENTER 1600/290

		U.S. PATEN	T DOCUMENTS			
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date
	4,650,764	03/17/87	Temin et al.			
	4,797,368	01/10/89	Carter et al.			
	4,873,316	10/10/89	Meade et al.			
	4,980,289	12/25/90	Temin et al.			
	5,124,263	06/23/92	Temin et al.			
	5,139,941	08/18/92	Muzyczka et al.			
	5,168,062	12/01/92	Stinski			
	5,302,697	04/12/94	Goodey et al.			
	5,385,839	01/31/95	Stinski			
	5,399,346	03/21/95	Anderson et al.			
	5,637,504	06/10/97	Hinchliffe et al.			
	5,648,243	07/15/97	Hurwitz et al.			· · · · · · · · · · · · · · · · · · ·
	5,780,009	06/14/98	Karatzas et al.			
	5,783,423	07/21/98	Wood et al.			

FOREIGN PATENT DOCUMENTS						
Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
EP 0 073 646 B1	05/17/89	EPO				
EP 0 178 220 B1	01/02/92	EPO				
EP 0 185 573 B1	05/20/92	EPO				
 EP 0 198 745 B1	05/16/90	EPO				
 EP 0 200 590 B1	07/19/89	EPO .			·	

Examiner		Date Considered
*Examiner:		e considered, whether or not citation is in conformance with MPEP 609; draw line f not in conformance and not considered. Include copy of this form with next o applicant.
Form PTO 14	49	Patent and Trademark Office - U.S. Department of Commerce

Atty. Docket No.	08888.0549	Appln. No.	09/763,210	RECEIVED
Applicant	Shian-Jiun SHIH et al.		·	Nov
Filing Date	October 16, 2001	Group:	1632	NOV 1 5 2002

FOREIGN PATENT DOCUMENTS TECH CENTER 1600/290						
Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
EP 0 201 239 B1	10/18/89	EPO				
EP 0 236 210 B1	10/23/91	EPO				
EP 0 319 067 B1	12/18/91	EPO				
EP 0 361 991 B1	12/15/99	EPO				
EP 0 453 242 B1	04/16/91	EPO				
EP 0 488 528 B1	10/29/91	EPO				
WO 91/18088	11/28/91	WIPO				
WO 93/09239	05/13/93	WIPO				
WO 94/12649	06/09/94	WIPO				
WO 94/26914	11/24/94	WIPO				
WO 94/28152	12/08/94	WIPO				
WO 94/28938	12/22/94	WIPO				
WO 95/02697	01/26/95	WIPO				
WO 95/07358	03/16/95	WIPO				
WO 95/23857	09/08/95	WIPO				
WO 96/01313	01/18/96	WIPO			***************************************	
WO 96/22378	07/25/96	WIPO				
WO 97/33975	09/18/97	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Adams, J., et al., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature, 318:533-538 (1985).					

Examiner		Date Considered
*Examiner:		nsidered, whether or not citation is in conformance with MPEP 609; draw line tin conformance and not considered. Include copy of this form with next oplicant.
Form PTO 14	149	Patent and Trademark Office - U.S. Department of Commerce

Atty. Docket No.	08888.0549	Appln. No.	09/763,210	RECEIVE		
Applicant	Shian-Jiun SHIH et al.			NOV -		
Filing Date	October 16, 2001	Group:	1632	**** 1 5 200		
				TECH CENTER 1600		
	OTHER DOCUMENTS (Including Au			·		
	Alexander, W., et al., Expression of the Enhancer in Eµ-myc Transgenic Mice	ne c- <i>myc O</i> nc e, Molecular a	ogene under Control ond Cellular Biology, 7:	of an Immunoglobulin :1436-1444 (1986).		
	Beard, C., <i>et al.</i> , Transcription Mappi 175:81-90 (1990).	ng of Mouse A	Adenovirus Type 1 Ea	rly Region 3, Virology,		
	Benoist, C., et al., In vivo sequence re 290:304-310 (1981).	equirements o	of the SV40 early prom	noter region, Nature,		
	Bernstein, A., et al., Gene Transfer w Methods, J.K. Setlow and A. Hollaend	ith Retrovirus der (Eds.), Ple	Vectors, In Genetic E enum Press, New York	ngineering Principles and (1985), pp. 235-261.		
	Brinster, R., et al., Regulation of meta mouse eggs, Nature, 296:39-42 (198:	allothionein-th 2).	ymidine kinase fusion	plasmids injected into		
	Brown, J., Serum Albumin: Amino Ac Rosenoer, V.M. et al. (eds.), Pergamo	d Sequence, on Press, Oxfo	Albumin Structure, Fu ord, 27-51 (1977).	inction and Uses,		
	Cannon, J., et al., The Effect of Aggregation Inhibitors and Antioxidants on the Stability of Hemin Solutions, PDA Journal of Pharm. Sci. and Tech., 49:77-82 (1995).					
	Chang, A., et al., Stabilization of Tetanus Toxoid in Poly(DL-lactic-co-glycolic acid) Microspher for the Controlled Release of Antigen, Pharm. Sci., 85:129-132 (1996).					
	Cohn, E., et al., Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids, Journal of the Am. Chem. Soc., 68:459-475 (1946).					
	de Boer, H., et al., The tac promoter: A functional hybrid derived from the trp and lac promoters, Pro. Natl. Acad. Sci. USA, 80:21-25 (1983).					
	Etcheverry, T., et al., Regulation of the Albumin or Yeast Phosphoglycerate k	e Chelatin Pro (inase in Yeas	omoter During the Exp st, Bio/Technology, 4:7	ression of Human Serum 726-730 (1986).		
	Gilbert, W., et al., Useful Proteins from (1980).	n Recombinar	nt Bacteria, Scientific /	American, 242: 74-94		
	Graham, F., Characteristics of a Hum. Type 5, The Journal of General Virolo	an Cell Line T gy, 36:59-72 (ransformed by DNA fr (1977).	rom Human Adenovirus		

Examiner		Date Considered
*Examiner:	Initial if reference through citation if communication to	considered, whether or not citation is in conformance with MPEP 609; draw line finot in conformance and not considered. Include copy of this form with next papplicant.
Form PTO 14	149	Patent and Trademark Office - U.S. Department of Commerce

Journal, 3:2917-2922 (1984).

Graham, F., Covalently closed circles of human adenovirus DNA are infectious, The EMBO

Atty. Docket No.	08888.0549	Appln. No.	09/763,210
Applicant	Shian-Jiun SHIH et al.		
Filing Date	October 16, 2001	Group:	1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Grosschedl, R., <i>et al.</i> , Introduction of a µ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody, Cell, 38:647-658 (1984).
Hammer, R., et al., Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer Elements, Science, 235:53-58 (1987)
Hanahan, D., Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, Nature, 315:115-122 (1985).
Kelsey, G., et al., Species- and tissue-specific expression of human α ₁ -antitrypsin in transgenic mice, Genes & Development, 1:161-171 (1987).
Kollias, G., <i>et al.</i> , Regulated Expression of Human ^A γ-, β-, and Hybrid γβ-Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns, Cell, 46:89-94 (1986).
Krumlauf, R., <i>et al.</i> , Developmental Regulation of α-Fetoprotein Genes in Transgenic Mice, Molecular and Cellular Biology, 5:1639-1648 (1985).
Kuo, M., et al., Efficient Gene Transfer Into Primary Murine Lymphocytes Obviating the Need for Drug Selection, Blood, 82:845-852 (1993).
Leder, A., et al., Consequences of Widespread Deregulation of the c-myc Gene in Transgenic Mice: Multiple Neoplasms and Normal Development, Cell, 45:485-495 (1986).
Levrero, M., et al., Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo, Gene, 101:195-202 (1991).
Magram, J., <i>et al.</i> , Developmental regulation of a cloned adult β-globin gene in transgenic mice, Nature, 315:338-340 (1985).
 Mann, R., et al., Construction of a Retrovirus Packaging Mutant and Its Use to Produce Helper-Free Defective Retrovirus, Cell, 33:153-159 (1983).
Markowitz, D., et al., A Safe Packaging Line for Gene Transfer: Separating Viral Genes on Two Different Plasmids, Journal of Virology, 62:1120-1124 (1988).
Mason, A., et al., The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy, Science, 234:1372-1378 (1986).
McCormick, D., Human Gene Therapy: The First Round, Bio/Technology, 3:689-693 (1985).
McDonald, J., <i>et al.</i> , Diminished Responsiveness of Male Homosexual Chronic Hepatitis B Virus Carriers with HTLV-III Antibodies to Recombinant α-Interferon, Hepatology, 7:719-723 (1987).

Examiner	1	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		conformance and not considered. Include copy of this form with next
Form PTO 14	149	Patent and Trademark Office - U.S. Department of Commerce

Atty. Docket No.	08888.0549	Appln. No.	09/763,210	
Applicant	Shian-Jiun SHIH et al.			
Filing Date	October 16, 2001	Group:	1632	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Niemeijer, N., et al., Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts, Annals of Allergy, Asthma, & Immunology, 76:535-540 (1996).
Ornitz, D., et al., Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice, Cold Spring Harbor Symposia on Quantitative Biology, L:399-409 (1985).
Paige, A., et al., Prolonged Circulation of Recombinant Human Granulocyte-Colony Stimulating Factor by Covalent Linkage to Albumin Through a Heterobifunctional Polyethylene Glycol, Pharmaceutical Res., 12:1883-1888 (1995).
Pinkert, C., et al., An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice, Genes & Development, 1:268-276 (1987).
Readhead, C., et al., Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice: Correction of the Dysmyelinating Phenotype, Cell, 48:703-712 (1987).
Saunders, C., et al., Secretion of Human Serum Albumin from Bacillus subtilis, Journal of Bacteriol, 169:2917-2925 (1987).
Shani, M., Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice, Nature, 314:283-286 (1985).
Swift, G., et al., Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice, Cell. 38:639-646 (1984).
Villa-Komaroff, L., et al., A bacterial clone synthesizing proinsulin, Proc. Natl. Acad. Sci. USA, 75:3727-3731 (1978).
Wagner, M., et al., Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1; Proc. Natl. Acad. Sci. USA, 78:1441-1445 (1981).
Weitkamp, L., et al., Additional data on the population distribution of human serum albumin genes; three new variants, Ann. Hum. Genet., 37:219-226 (1973).
Yamamoto, T., et al., Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus, Cell, 22:787-797 (1980).

Examiner		Date Considered
*Examiner:	niner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 14	149	Patent and Trademark Office - U.S. Department of Commerce